DK1100792T3 - Tricycliske sulfonamider og derivater deraf som inhibitorer af matrix-metalloproteinaser - Google Patents
Tricycliske sulfonamider og derivater deraf som inhibitorer af matrix-metalloproteinaserInfo
- Publication number
- DK1100792T3 DK1100792T3 DK99963141T DK99963141T DK1100792T3 DK 1100792 T3 DK1100792 T3 DK 1100792T3 DK 99963141 T DK99963141 T DK 99963141T DK 99963141 T DK99963141 T DK 99963141T DK 1100792 T3 DK1100792 T3 DK 1100792T3
- Authority
- DK
- Denmark
- Prior art keywords
- inhibitors
- derivatives
- matrix metalloproteinases
- tricyclic sulfonamides
- sulfonamides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/76—Dibenzothiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
- H04M15/28—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP with meter at substation or with calculation of charges at terminal
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
- H04M15/28—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP with meter at substation or with calculation of charges at terminal
- H04M15/30—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP with meter at substation or with calculation of charges at terminal the meter or calculation of charges not being controlled from an exchange
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
- H04M15/31—Distributed metering or calculation of charges
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
- H04M15/49—Connection to several service providers
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
- H04M15/80—Rating or billing plans; Tariff determination aspects
- H04M15/8044—Least cost routing
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
- H04M15/83—Notification aspects
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
- H04M2215/01—Details of billing arrangements
- H04M2215/0168—On line or real-time flexible customization or negotiation according to wishes of subscriber
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
- H04M2215/42—Least cost routing, i.e. provision for selecting the lowest cost tariff
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
- H04M2215/46—Connection to several service providers
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
- H04M2215/74—Rating aspects, e.g. rating parameters or tariff determination apects
- H04M2215/745—Least cost routing, e.g. Automatic or manual, call by call or by preselection
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
- H04M2215/82—Advice-of-Charge [AOC], i.e. notify subscriber of charges/cumulative charge; meter at the substation
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
- H04M2215/92—Autonomous calculations of charges in terminal, i.e. meter not controlled from exchange
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
- H04M2215/96—Distributed calculation of charges, e.g. in different nodes like for mobiles between HLR and VLR, or between the terminal and the billing function
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Computer Networks & Wireless Communication (AREA)
- Signal Processing (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9500698P | 1998-07-30 | 1998-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1100792T3 true DK1100792T3 (da) | 2004-07-05 |
Family
ID=22248526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99963141T DK1100792T3 (da) | 1998-07-30 | 1999-06-02 | Tricycliske sulfonamider og derivater deraf som inhibitorer af matrix-metalloproteinaser |
Country Status (32)
Country | Link |
---|---|
US (2) | US6420408B1 (fr) |
EP (1) | EP1100792B1 (fr) |
JP (1) | JP2002521478A (fr) |
KR (1) | KR20010072089A (fr) |
CN (1) | CN1310716A (fr) |
AP (1) | AP2001002037A0 (fr) |
AT (1) | ATE261954T1 (fr) |
AU (1) | AU758619B2 (fr) |
BG (1) | BG105185A (fr) |
BR (1) | BR9912600A (fr) |
CA (1) | CA2335077A1 (fr) |
DE (1) | DE69915634T2 (fr) |
DK (1) | DK1100792T3 (fr) |
EA (1) | EA200100158A1 (fr) |
EE (1) | EE200100063A (fr) |
ES (1) | ES2216614T3 (fr) |
GE (1) | GEP20033052B (fr) |
HR (1) | HRP20010078A2 (fr) |
HU (1) | HUP0102714A3 (fr) |
ID (1) | ID27192A (fr) |
IL (1) | IL140746A0 (fr) |
IS (1) | IS5810A (fr) |
NO (1) | NO20010479D0 (fr) |
NZ (1) | NZ509439A (fr) |
OA (1) | OA11589A (fr) |
PL (1) | PL345776A1 (fr) |
PT (1) | PT1100792E (fr) |
SK (1) | SK1192001A3 (fr) |
TR (1) | TR200100239T2 (fr) |
WO (1) | WO2000006561A1 (fr) |
YU (1) | YU6701A (fr) |
ZA (1) | ZA200100455B (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6846799B1 (en) | 1998-08-18 | 2005-01-25 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
US7354894B2 (en) | 1998-08-18 | 2008-04-08 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
MXPA01013171A (es) | 2001-02-14 | 2004-05-21 | Warner Lambert Co | Inhibidores triciclicos de sulfonamida de metaloproteinasa de matriz. |
CN1304390C (zh) * | 2001-08-03 | 2007-03-14 | 先灵公司 | 新颖的γ—分泌酶抑制剂 |
US20040235957A1 (en) * | 2001-10-12 | 2004-11-25 | David Bleakman | Use of sulfonamide derivatives as pharmaceuticals compounds |
KR100966705B1 (ko) * | 2001-12-20 | 2010-06-29 | 브리스톨-마이어스 스큅 컴퍼니 | β-아밀로이드 저해제로서의α-(Ν-술폰아미도)아세트아미드 유도체 |
IL165265A0 (en) * | 2002-06-11 | 2005-12-18 | Wyeth Corp | Substituted phenylsulfonamide inhibitors of beta amyloid production |
EP1530467A2 (fr) * | 2002-07-17 | 2005-05-18 | Warner-Lambert Company LLC | Combinaison d'un inhibiteur carboxylique allosterique de metalloproteinase-13 de matrice et de celecoxibe ou de valdecoxibe |
US20050095267A1 (en) * | 2002-12-04 | 2005-05-05 | Todd Campbell | Nanoparticle-based controlled release polymer coatings for medical implants |
EP1594459B1 (fr) | 2002-12-30 | 2010-02-17 | Angiotech International Ag | Liberation de medicaments a partir d'une composition polymere a gelification rapide |
WO2004089294A2 (fr) | 2003-04-04 | 2004-10-21 | Incyte Corporation | Compositions, procedes et kits relatifs au clivage de her-2 |
EP2330132B1 (fr) | 2003-04-04 | 2013-08-14 | Yeda Research and Development Co. Ltd. | Anticorps contre MMP2 ou MMP9 et compositions pharmaceutiques contenant ces anticorps utiles pour inhiber l'activité de cettes métalloprotéines |
WO2005061448A1 (fr) * | 2003-12-24 | 2005-07-07 | Monash University | Compositions et methodes de traitement d'affections vasculaires |
US20060112494A1 (en) * | 2004-12-01 | 2006-06-01 | David Oppong | Method of protecting an animal skin product from metalloproteinase activity |
US8324355B2 (en) | 2007-02-23 | 2012-12-04 | Yeda Reearch and Development Co. Ltd | Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins |
US8012947B2 (en) * | 2007-03-15 | 2011-09-06 | Hospital For Special Surgery | Methods and compositions for promoting wound healing |
US20090285840A1 (en) * | 2008-04-29 | 2009-11-19 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Methods for treating pathological neovascularization |
CA2676946A1 (fr) | 2009-08-28 | 2011-02-28 | Lucie Peduto | Inhibiteurs de l'enzyme adam12 et leur utilisation contre la fibrose induite par l'inflammation |
CN103249719A (zh) | 2010-09-24 | 2013-08-14 | 兰贝克赛实验室有限公司 | 基质金属蛋白酶抑制剂 |
EP3410849B1 (fr) | 2016-02-05 | 2023-07-05 | Institut Pasteur | Utilisation d'inhibiteurs d'adam12 comme adjuvants dans les traitement antitumoraux |
CN114981251B (zh) * | 2020-01-21 | 2023-11-21 | 深圳信立泰药业股份有限公司 | 一种二苯并呋喃类衍生物组织蛋白酶k抑制剂及其制备方法和医药用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH517064A (de) * | 1969-07-09 | 1971-12-31 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Aryloxy- und Arylthioessigsäurederivaten |
CH530388A (de) * | 1970-03-20 | 1972-11-15 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Aryloxy- und Arylthioalkansäureamiden |
PH31294A (en) * | 1992-02-13 | 1998-07-06 | Thomae Gmbh Dr K | Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them. |
ATE206416T1 (de) | 1995-06-02 | 2001-10-15 | Warner Lambert Co | Trizyklische verbindungen als matrix- metalloproteinase inhibitoren |
US5883940A (en) | 1996-07-01 | 1999-03-16 | Teledynamics Group, Inc. | Interactive method and apparatus for the generation of leads |
ATE282602T1 (de) | 1996-08-16 | 2004-12-15 | Warner Lambert Co | Buttersäure matrix-metalloproteinase-inhibitoren |
WO1998009957A1 (fr) * | 1996-09-04 | 1998-03-12 | Warner-Lambert Company | Composes et procede destines a l'inhibition de metalloproteases matricielles |
EP0931045A1 (fr) * | 1996-09-04 | 1999-07-28 | Warner-Lambert Company | Inhibiteurs de metalloproteinases matricielles et leurs utilisations pharmaceutiques |
BR9712525A (pt) * | 1996-10-16 | 1999-10-19 | American Cyanamid Co | O preparo e uso de ácidos orto-sulfonamido aril hidroxmicos como inibidores da metaloproteinase matricial e da tace |
-
1999
- 1999-06-02 AT AT99963141T patent/ATE261954T1/de not_active IP Right Cessation
- 1999-06-02 GE GEAP19995773A patent/GEP20033052B/en unknown
- 1999-06-02 HU HU0102714A patent/HUP0102714A3/hu unknown
- 1999-06-02 NZ NZ509439A patent/NZ509439A/xx unknown
- 1999-06-02 EP EP99963141A patent/EP1100792B1/fr not_active Expired - Lifetime
- 1999-06-02 DK DK99963141T patent/DK1100792T3/da active
- 1999-06-02 SK SK119-2001A patent/SK1192001A3/sk unknown
- 1999-06-02 EA EA200100158A patent/EA200100158A1/ru unknown
- 1999-06-02 ES ES99963141T patent/ES2216614T3/es not_active Expired - Lifetime
- 1999-06-02 TR TR2001/00239T patent/TR200100239T2/xx unknown
- 1999-06-02 PL PL99345776A patent/PL345776A1/xx not_active Application Discontinuation
- 1999-06-02 WO PCT/US1999/012273 patent/WO2000006561A1/fr not_active Application Discontinuation
- 1999-06-02 BR BR9912600-1A patent/BR9912600A/pt not_active IP Right Cessation
- 1999-06-02 ID IDW20010198A patent/ID27192A/id unknown
- 1999-06-02 KR KR1020017001206A patent/KR20010072089A/ko not_active Application Discontinuation
- 1999-06-02 IL IL14074699A patent/IL140746A0/xx unknown
- 1999-06-02 AU AU43292/99A patent/AU758619B2/en not_active Ceased
- 1999-06-02 CN CN99808838A patent/CN1310716A/zh active Pending
- 1999-06-02 JP JP2000562364A patent/JP2002521478A/ja active Pending
- 1999-06-02 DE DE69915634T patent/DE69915634T2/de not_active Expired - Fee Related
- 1999-06-02 YU YU6701A patent/YU6701A/sh unknown
- 1999-06-02 CA CA002335077A patent/CA2335077A1/fr not_active Abandoned
- 1999-06-02 EE EEP200100063A patent/EE200100063A/xx unknown
- 1999-06-02 OA OA1200100027A patent/OA11589A/en unknown
- 1999-06-02 PT PT99963141T patent/PT1100792E/pt unknown
- 1999-06-02 AP APAP/P/2001/002037A patent/AP2001002037A0/en unknown
-
2001
- 2001-01-12 IS IS5810A patent/IS5810A/is unknown
- 2001-01-16 ZA ZA200100455A patent/ZA200100455B/en unknown
- 2001-01-25 BG BG105185A patent/BG105185A/xx unknown
- 2001-01-29 NO NO20010479A patent/NO20010479D0/no not_active Application Discontinuation
- 2001-01-30 HR HR20010078A patent/HRP20010078A2/hr not_active Application Discontinuation
- 2001-04-10 US US09/719,027 patent/US6420408B1/en not_active Expired - Fee Related
-
2002
- 2002-03-27 US US10/108,817 patent/US6492422B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1100792T3 (da) | Tricycliske sulfonamider og derivater deraf som inhibitorer af matrix-metalloproteinaser | |
DK0923585T3 (da) | Phosphinatbaserede inhibitorer af matrixmetalloproteinaser | |
NO20005265D0 (no) | Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser | |
NO991922D0 (no) | Heteroarylsuccinamider og deres anvendelse som metalloproteinaseinhibitorer | |
NO992492D0 (no) | Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer | |
DK1133477T3 (da) | Substituerede benzimidazoler og deres anvendelse som parpinhibitorer | |
NO996313D0 (no) | Nye amidinoderivater og deres anvendelse som trombininhibitorer | |
NO20026010D0 (no) | Substituerte quinazolinderivater og deres anvendelse som inhibitorer | |
DK1288206T3 (da) | Substituerede benzensulfonamidderivater som prolægemidler af COX-2-inhibitorer | |
DK1347955T3 (da) | Nye mandelsyrederivater og deres anvendelse som throbin-hæmmere | |
NO986180D0 (no) | Nye amidinoderivater og deres anvendelse som trombininhibitorer | |
DK1086076T3 (da) | Sulfonamidinhibitorer af aspartylprotease | |
DK1170288T3 (da) | Diphenylurinstofderivater og deres anvendelse som alfa2/5-HT2c-antagonister | |
DK0989121T3 (da) | Substituerede benzamider og deres anvendelse som immunmodulatorer | |
DK1686113T3 (da) | Inhibitorer af aspartylprotease | |
NO20026262L (no) | Cyklopentyl-substituerte glutaramidderivater som inhibitorer av nöytral endopeptidase | |
NO20042719L (no) | Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer | |
DK1047450T3 (da) | Kombinationer af ACE-inhibitorer og MMP-inhibitorer | |
NO20034995D0 (no) | Aromatiske sulfonhydroksymater og deres anvendelse som proteaseinhibitorer | |
IS5772A (is) | Þalazín (phthalazine) afleiður af fosfódíesterasa4 lötum | |
DK1150996T3 (da) | Nye amidinobenzylaminderivater og deres anvendelse som thrombin-inhibitorer | |
DK0928291T3 (da) | 3-Mercaptoacetylamino-1,5-substituerede 2-oxo-azepanderivater, der er nyttige som inhibitorer af matrixmetalloproteinase | |
NO20023956L (no) | Priperidin- og piperazinsubstituerte N-hydroksyformamider som inhibitorer av metalloproteinaser | |
DK1299365T3 (da) | 2-aminothiazolinderivater og deres anvendelse som inhibitorer for NO-synthase | |
DK1147101T3 (da) | Omvendt-hydroxamat-inhibitorer af matrix-metalloproteinaser |